1. Lurain JR: Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. AM J OBSTET GYNECOL 2010, 203(6):531–539.
2.Mehlen P, Puisieux A: Metastasis: a question of life or death. NAT REV CANCER 2006, 6(6):449–458.
3.Berkowitz RS, Goldstein DP: Current advances in the management of gestational trophoblastic disease. GYNECOL ONCOL 2013, 128(1):3–5.
4.Shukla V, Adiga D, Jishnu PV, Varghese VK, Satyamoorthy K, Kabekkodu SP: Role of miRNA clusters in epithelial to mesenchymal transition in cancer. Front Biosci (Elite Ed) 2020, 12:48–78.
5.Shin VY, Chu KM: MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol 2014, 20(30):10432–10439.
6.Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY et al: Human embryonic stem cells express a unique set of microRNAs. DEV BIOL 2004, 270(2):488–498.
7.Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Guckel B, Fehm T, Schneeweiss A et al: MicroRNA–520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. ONCOGENE 2012, 31(37):4150–4163.
8.Qiu X, Zhu J, Sun Y, Fan K, Yang DR, Li G, Yang G, Chang C: TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR–373–3p expression to alter TGFbetaR2/p-Smad3 signals. Oncotarget 2015, 6(17):15397–15409.
9.Das V, Bhattacharya S, Chikkaputtaiah C, Hazra S, Pal M: The basics of epithelial-mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective. J CELL PHYSIOL 2019.
10.E DJ, Pollheimer J, Yong HE, Kokkinos MI, Kalionis B, Knofler M, Murthi P: Epithelial-mesenchymal transition during extravillous trophoblast differentiation. Cell Adh Migr 2016, 10(3):310–321.
11.Turini S, Bergandi L, Gazzano E, Prato M, Aldieri E: Epithelial to Mesenchymal Transition in Human Mesothelial Cells Exposed to Asbestos Fibers: Role of TGF-beta as Mediator of Malignant Mesothelioma Development or Metastasis via EMT Event. INT J MOL SCI 2019, 20(1).
12.Howley BV, Howe PH: TGF-beta signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1. CYTOKINE 2019, 118:19–26.
13.Park SH, Cho HJ, Jeong YJ, Shin JM, Kang JH, Park KK, Choe JY, Park YY, Bae YS, Han SM et al: Melittin inhibits TGF-beta-induced pro-fibrotic gene expression through the suppression of the TGFbetaRII-Smad, ERK1/2 and JNK-mediated signaling pathway. Am J Chin Med 2014, 42(5):1139–1152.
14.Tan Y, Xu Q, Li Y, Mao X, Zhang K: Crosstalk between the p38 and TGF-beta signaling pathways through TbetaRI, TbetaRII and Smad3 expression in plancental choriocarcinoma JEG–3 cells. ONCOL LETT 2014, 8(3):1307–1311.
15.Li Y, Xu Q, Zhang Z, Liu S, Shi C, Tan Y: The impact of TGF-beta1 on the mRNA expression of TbetaR I, TbetaR II, Smad4 and the invasiveness of the JEG–3 placental choriocarcinoma cell line. ONCOL LETT 2012, 4(6):1344–1348.
16.Huang Y, Zhang Z, Huang Y, Mao Z, Yang X, Nakamura Y, Sawada N, Mitsui T, Takeda M, Yao J: Induction of inactive TGF-beta1 monomer formation by hydrogen sulfide contributes to its suppressive effects on Ang II- and TGF-beta1-induced EMT in renal tubular epithelial cells. Biochem Biophys Res Commun 2018, 501(2):534–540.
17.Hatta M, Miyake Y, Uchida K, Yamazaki J: Keratin 13 gene is epigenetically suppressed during transforming growth factor-beta1-induced epithelial-mesenchymal transition in a human keratinocyte cell line. Biochem Biophys Res Commun 2018, 496(2):381–386.
18.E DJ, Pollheimer J, Yong HE, Kokkinos MI, Kalionis B, Knofler M, Murthi P: Epithelial-mesenchymal transition during extravillous trophoblast differentiation. Cell Adh Migr 2016, 10(3):310–321.
19.Kokkinos MI, Murthi P, Wafai R, Thompson EW, Newgreen DF: Cadherins in the human placenta—epithelial-mesenchymal transition (EMT) and placental development. PLACENTA 2010, 31(9):747–755.
20.Nakaya Y, Sheng G: EMT in developmental morphogenesis. CANCER LETT 2013, 341(1):9–15.
21.Dubruc E, Allias F, Morel AP, Golfier F, Puisieux A, Devouassoux-Shisheboran M: Gestational trophoblastic neoplasms (GTNs) do not display epithelial-to-mesenchymal transition (EMT) features. VIRCHOWS ARCH 2019, 475(1):121–125.
22.Wong O, Cheung C, Ip P, Ngan H, Cheung A: Amyloid Precursor Protein Overexpression in Down Syndrome Trophoblast Reduces Cell Invasiveness and Interferes with Syncytialization. AM J PATHOL 2018, 188(10):2307–2317.
23.Xu G, Guimond MJ, Chakraborty C, Lala PK: Control of proliferation, migration, and invasiveness of human extravillous trophoblast by decorin, a decidual product. BIOL REPROD 2002, 67(2):681–689.
24.Khaled N, Bidet Y: New Insights into the Implication of Epigenetic Alterations in the EMT of Triple Negative Breast Cancer. Cancers (Basel) 2019, 11(4).
25.Shi Y, Shi H, Zhang B, Yan Y, Han X, Jiang W, Qian H, Xu W: miR–373 suppresses gastric cancer metastasis by downregulating vimentin. MOL MED REP 2018, 17(3):4027–4034.
26.Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ et al: The microRNAs miR–373 and miR–520c promote tumour invasion and metastasis. NAT CELL BIOL 2008, 10(2):202–210.
27.Bordignon P, Bottoni G, Xu X, Popescu AS, Truan Z, Guenova E, Kofler L, Jafari P, Ostano P, Rocken M et al: Dualism of FGF and TGF-beta Signaling in Heterogeneous Cancer-Associated Fibroblast Activation with ETV1 as a Critical Determinant. CELL REP 2019, 28(9):2358–2372.
28.Mu Y, Li N, Cui YL: The lncRNA CCAT1 upregulates TGFbetaR1 via sponging miR–490–3p to promote TGFbeta1-induced EMT of ovarian cancer cells. CANCER CELL INT 2018, 18:145.
29.Ibrahim MG, Elghonaimy EA, Schafer S, Vennemann M, Kliesch S, Kiesel L, Gotte M, Schuring AN: Seminal plasma (SP) induces a rapid transforming growth factor beta 1 (TGFbeta1)-independent up-regulation of epithelial-mesenchymal transdifferentiation (EMT) and myofibroblastic metaplasia-markers in endometriotic (EM) and endometrial cells. ARCH GYNECOL OBSTET 2019, 299(1):173–183.